专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US08916175B2 Safer attenuated varicella-zoster virus vaccines with missing or diminished latency of infection 有权
标题翻译：更安全的减毒水痘带状疱疹病毒疫苗缺失或减少的潜伏期的感染
公开(公告)号：US08916175B2
公开(公告)日：2014-12-23
申请号：US11630147
申请日：2005-06-22
申请人： Jeffrey I. Cohen , Edward M. Cox, Jr. , Lesley M. Pesnicak
发明人： Jeffrey I. Cohen , Edward M. Cox, Jr. , Lesley M. Pesnicak
IPC分类号： A61K39/25 , A01N63/00 , C12N7/00 , C12N7/04
CPC分类号： A61K39/25 , A61K39/12 , C12N7/00 , C12N2710/16734 , C12N2710/16761 , C12N2710/16762
摘要： Viruses having weakened ability to establish and/or maintain latency and their use as live vaccines are described. The vaccines have one or more alterations in genes that provide continued virus replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the varicella zoster virus. Deletion of a significant portion from both copies of the varicella zoster gene ORF63 was shown to inhibit establishment of a latent infection from a live vaccine form of the virus. Insertion of an additional ORF62 gene which is partially truncated with the ORF63 deletion inhibited establishment of latency and allowed normal growth of the virus. Other desirable viral antigen encoding sequence(s) and/or cytokine genes advantageously may replace deleted genetic material to enhance a desired immunological response. Aspects of the discovery pertain to live vaccines of other viruses, and can provide a variety of vaccines having greater safety.
摘要翻译：描述了具有削弱建立和/或维持延迟的能力及其作为活疫苗的用途的病毒。疫苗在提供持续病毒复制但抑制潜伏期的基因中具有一个或多个改变。用于其构建的疫苗材料和方法以水痘带状疱疹病毒为例。从水痘带状疱疹基因ORF63的两个拷贝中删除重要部分被证明可以抑制病毒活疫苗形式的潜伏感染的建立。用ORF63缺失部分截断的另外的ORF62基因的插入抑制了潜伏期的建立并允许病毒的正常生长。其他所需的病毒抗原编码序列和/或细胞因子基因有利地可以代替缺失的遗传物质以增强所需的免疫应答。该发现的方面涉及其他病毒的活疫苗，并且可以提供具有更高安全性的多种疫苗。

22. 发明授权

US08765139B2 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals 有权
标题翻译：具有改变的干扰素拮抗剂活性的减毒负链病毒用作疫苗和药物
公开(公告)号：US08765139B2
公开(公告)日：2014-07-01
申请号：US13250846
申请日：2011-09-30
申请人： Peter Palese , Adolfo Garcia-Sastre , Thomas Muster
发明人： Peter Palese , Adolfo Garcia-Sastre , Thomas Muster
IPC分类号： A61K39/145 , A61K39/12 , A01N63/00 , A61K39/38 , A61K39/25
CPC分类号： A61K39/145 , A61K39/0011 , A61K39/12 , A61K39/155 , A61K39/17 , A61K39/205 , A61K2039/525 , A61K2039/5254 , A61K2039/5256 , A61K2039/543 , A61K2039/552 , A61K2039/572 , A61K2039/585 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2760/16121 , C12N2760/16122 , C12N2760/16132 , C12N2760/16134 , C12N2760/16143 , C12N2760/16151 , C12N2760/16161 , C12N2760/16162 , C12N2760/16171 , C12N2760/16221 , C12N2760/16222 , C12N2760/16232 , C12N2760/16234 , C12N2760/16243 , C12N2760/16251 , C12N2760/16262 , C12N2760/16271 , C12N2760/18022 , C12N2760/18034 , C12N2760/18122 , C12N2760/18134 , C12N2760/18522 , C12N2760/18534 , C12N2760/20222 , C12N2760/20234 , Y02A50/466
摘要： The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses.In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.
摘要翻译：本发明一般涉及具有拮抗细胞干扰素（IFN）应答能力受损的减毒负链RNA病毒，以及在疫苗和药物制剂中使用这种减毒病毒。本发明还涉及用于选择这种减毒病毒的IFN-缺陷系统的开发和应用。具体地，本发明涉及具有修饰的NS1基因的减毒流感病毒，其减少或消除NS1基因产物拮抗细胞IFN应答的能力。突变体病毒在体内复制但表现出降低的致病性，因此非常适合于活病毒疫苗和药物制剂。

23. 发明授权

US07989162B2 Viral variants with altered susceptibility to nucleoside analogs and uses thereof 有权
标题翻译：对核苷类似物具有改变的易感性的病毒变体及其用途
公开(公告)号：US07989162B2
公开(公告)日：2011-08-02
申请号：US12142917
申请日：2008-06-20
申请人： Angeline Ingrid Bartholomeusz , Stephen Alister Locarnini , Anna Ayres , Peter William Angus , William Sievert
发明人： Angeline Ingrid Bartholomeusz , Stephen Alister Locarnini , Anna Ayres , Peter William Angus , William Sievert
IPC分类号： C12Q1/70 , A61K39/00 , A61K39/29 , A61K39/25
CPC分类号： C07K14/005 , A61K39/00 , C12N7/00 , C12N2730/10122 , C12Q1/706
摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
摘要翻译：本发明一般涉及对特定试剂表现出降低的敏感性和/或降低与免疫试剂的相互作用的病毒变体。更具体地，本发明涉及对核苷类似物表现完全或部分抗性和/或与抗体对抗病毒表面成分降低的相互作用的乙型肝炎病毒（HBV）变体，包括对这些抗体的敏感性降低。本发明进一步考虑了用于检测此类病毒变体的测定法，该测定法可用于监测抗病毒治疗方案和开发针对病毒剂，特别是HBV变体的新的或修饰的疫苗。本发明还考虑使用病毒变体筛选能够抑制病毒感染，复制和/或释放的药剂。

24. 发明申请

US20100247537A1 ADJUVANT COMBINATIONS OF NKT ACTIVATOR, CD40 AGONIST, AND OPTIONAL ANTIGEN, THE USE THROUGH INDUCING SYNERGISTIC CELLULAR IMMUNITY 有权
标题翻译： NKT激活剂，CD40激动剂和可选抗原的补充剂组合，通过诱导协同细胞免疫的用途
公开(公告)号：US20100247537A1
公开(公告)日：2010-09-30
申请号：US12597615
申请日：2008-04-25
申请人： Cory Ahonen , Randolph Noelle
发明人： Cory Ahonen , Randolph Noelle
IPC分类号： A61K39/39 , A61K39/395 , A61K39/00 , A61K39/12 , A61K39/21 , A61K39/155 , A61K39/165 , A61K39/125 , A61K39/20 , A61K39/215 , A61K39/205 , A61K39/245 , A61K39/25 , A61K39/275 , A61K39/02 , A61K39/09 , A61K39/05 , A61K39/07 , A61K39/08 , A61K39/102 , A61K39/108 , A61K39/112 , A61K39/104 , A61K39/106 , A61K39/005 , A61K39/015 , A61K39/002 , C12N1/00
CPC分类号： A61K39/39 , A61K31/7032 , A61K39/29 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/55511 , A61K2039/55516 , A61K2039/57 , C07K16/2878 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/74 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要： Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.
摘要翻译：公开了包含至少一种NKT活化剂，例如α-半乳糖神经酰胺（α-Gal-Cer）或iGb3，CD40激动剂和任选的抗原的佐剂组合。还提供了这些免疫佐剂用于治疗各种慢性疾病如癌症的用途。

25. 发明申请

US20100047277A1 VIROSOMES, METHODS OF PREPARATION, AND IMMUNOGENIC COMPOSITIONS 审中-公开
标题翻译：病毒，制备方法和免疫组化
公开(公告)号：US20100047277A1
公开(公告)日：2010-02-25
申请号：US12373595
申请日：2007-07-12
申请人： Richard W. Compans , Chinglai Yang , Qizhi Yao , Sang-moo Kang
发明人： Richard W. Compans , Chinglai Yang , Qizhi Yao , Sang-moo Kang
IPC分类号： A61K39/12 , A61K39/21 , A61K39/145 , A61K39/155 , A61K39/215 , A61K39/205 , A61K39/245 , A61K39/25 , C12Q1/70 , C12N15/00 , A61P31/12
CPC分类号： C12N7/00 , A61K39/12 , A61K39/21 , A61K2039/5256 , A61K2039/5258 , A61K2039/54 , A61K2039/545 , C07K2319/03 , C12N2710/14143 , C12N2740/12045 , C12N2740/13023 , C12N2740/15023 , C12N2740/15034 , C12N2760/12223 , C12N2760/12234 , C12N2760/14123 , C12N2760/14134 , C12N2810/6072
摘要： Briefly described, virosomes, methods of preparing virosomes, immunogenic compositions that include virosomes, and methods of eliciting an immune response using immunogenic compositions that include virosomes are described herein. A virosome can include at least one viral surface envelope glycoprotein expressed on the surface of the virosome. The virosome can also optionally include at least one adjuvant molecule expressed on the surface of the virosome.
摘要翻译：简要描述了病毒体，制备病毒体的方法，包括病毒体的免疫原性组合物，以及使用包含病毒颗粒的免疫原性组合物引发免疫应答的方法。病毒颗粒可以包括在病毒体表面上表达的至少一种病毒表面包膜糖蛋白。病毒颗粒还可以任选地包括在病毒体的表面上表达的至少一种佐剂分子。

26. 发明申请

US20090123367A1 Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases 审中-公开
标题翻译：可溶性糖胺聚糖酶和制备和使用可溶性糖胺聚糖的方法
公开(公告)号：US20090123367A1
公开(公告)日：2009-05-14
申请号：US11884862
申请日：2006-02-23
申请人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost , Michael F. Haller , Gilbert A. Keller , Tyler M. Dylan
发明人： Louis H. Bookbinder , Anirban Kundu , Gregory I. Frost , Michael F. Haller , Gilbert A. Keller , Tyler M. Dylan
IPC分类号： A61K51/10 , C12N9/26 , A61K38/47 , A61K49/00 , A61K39/395 , A61K38/21 , A61K39/09 , A61P35/00 , A61K39/25 , A61K39/165 , A61K38/20 , A61K39/13 , A61K39/145 , A61K39/29
CPC分类号： A61K38/47 , A61K39/3955 , C12N9/2408 , A61K2300/00
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
摘要翻译：本发明涉及新型可溶性中性活性透明质酸酶糖蛋白（sHASEGPs）的发现，其制备方法及其用于促进其它分子的施用或减轻糖胺聚糖相关病理学的用途。描述了可溶性中性活性sHASEGP结构域的微活性多肽结构域，其包括功能性中性活性透明质酸酶结构域所需的天冬酰胺连接的糖部分。包括改进的氨基末端前导肽，其增强sHASEGP的分泌。本发明还包含重组sHASEGP的唾液酸化和聚乙二醇化形式，以增强天然存在的屠宰酶的稳定性和血清药代动力学。进一步描述了衍生自真核细胞的基本上纯化的重组sHASEGP糖蛋白的合适制剂，其产生其最佳活性所需的适当糖基化。

27. 发明授权

US07422751B2 Epstein-barr-virus-specific immunization 失效
标题翻译：爱泼斯坦病毒特异性免疫
公开(公告)号：US07422751B2
公开(公告)日：2008-09-09
申请号：US10517800
申请日：2003-06-13
申请人： Esteban Celis
发明人： Esteban Celis
IPC分类号： A61K39/00 , A61K39/12 , A61K39/25
CPC分类号： C07K14/005 , A61K38/162 , A61K39/00 , A61K2039/555 , A61K2039/57 , C12N2710/16222 , C12N2710/16622
摘要： The invention provides materials and methods for using EBV EBNA2 peptide epitopes to treat and/or prevent post-transplant lymphoproliferative disorders (PTLD). The invention also provides compositions and articles of manufacture containing EBNA2 peptide epitopes that can be used to treat and/or prevent PTLD.
摘要翻译：本发明提供了使用EBV EBNA2肽表位治疗和/或预防移植后淋巴增生性疾病（PTLD）的材料和方法。本发明还提供含有可用于治疗和/或预防PTLD的EBNA2肽表位的组合物和制品。

28. 发明申请

US20070212329A1 Vaccine Compositions Comprising An Interleukin 18 And Saponin Adjuvant System 审中-公开
标题翻译：包含白细胞介素18和皂苷佐剂系统的疫苗组合物
公开(公告)号：US20070212329A1
公开(公告)日：2007-09-13
申请号：US10575838
申请日：2004-10-11
申请人： Claudine Bruck , Catherine Marie Gerard , Zdenka Jonak
发明人： Claudine Bruck , Catherine Marie Gerard , Zdenka Jonak
IPC分类号： A61K38/20 , A61K31/704 , A61K39/00 , A61K39/21 , A61K39/145 , A61K39/15 , A61K39/29 , A61K39/25 , A61K39/02 , A61K39/108 , A61K39/04 , A61K39/085 , A61K39/118 , A61K39/245 , A61K39/095 , A61K39/015
CPC分类号： A61K39/0011 , A61K39/12 , A61K39/39 , A61K2039/55505 , A61K2039/55527 , A61K2039/55561 , A61K2039/55566 , A61K2039/55572 , A61K2039/55577 , A61K2039/585 , C12N2710/20034 , Y02A50/412
摘要： This invention relates to a combination therapy that finds utility in the treatment or prophylaxis of infectious diseases, cancers, autoimmune diseases and related conditions. In particular, the combination therapy comprises the administration of a TH-1 cytokine, in particular, IL-18, and an immunogenic composition, in particular, a vaccine, comprising an antigen and a saponin adjuvant. In particular, the invention relates to the use of IL-18 or bioactive fragment or variant thereof and an immunogenic composition comprising a tumour-associated antigen and a saponin adjuvant, for the treatment of preneoplasic lesions or cancer.
摘要翻译：本发明涉及在治疗或预防感染性疾病，癌症，自身免疫疾病和相关病症中发挥效用的组合疗法。特别地，组合疗法包括施用TH-1细胞因子，特别是IL-18，以及免疫原性组合物，特别是包含抗原和皂苷佐剂的疫苗。特别地，本发明涉及IL-18或其生物活性片段或其变体和包含肿瘤相关抗原和皂苷佐剂的免疫原性组合物用于治疗原发性病变或癌症的用途。

29. 发明申请

US20060257428A1 Assays and therapies for latent viral infection 审中-公开
公开(公告)号：US20060257428A1
公开(公告)日：2006-11-16
申请号：US11405365
申请日：2006-04-17
申请人： John Harley , Judith James , Kenneth Kaufman
发明人： John Harley , Judith James , Kenneth Kaufman
IPC分类号： A61K39/25 , A61K39/245
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/545 , A61K2039/55566 , A61K2039/57 , C07K14/005 , C07K16/085 , C12N2710/16222 , C12N2710/16234
摘要： Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed. The antibody conjugates can be used in diagnostic assays to identify cells expressing latent viral protein and people who are harboring latent viral particles. The antibody conjugates can also be used to remove the infected cells or to kill the infected the cells. Alternatively, or in addition, the viral proteins or portions thereof can be used as a vaccine to induce an immune reaction by the host to kill the infected cells. These methods can be used to detect or treat patients harboring latent viruses like EBV and who are at risk of developing a disease such as an autoimmune disease like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

30. 发明授权

US06951651B2 CTL epitope analogs 有权
标题翻译： CTL表位类似物
公开(公告)号：US06951651B2
公开(公告)日：2005-10-04
申请号：US10643888
申请日：2003-08-20
申请人： Don J. Diamond
发明人： Don J. Diamond
IPC分类号： A61K39/245 , C12N15/10 , A61K38/00 , A61K39/12 , A61K39/25 , A61K39/38
CPC分类号： C12N15/1086 , A61K39/12 , A61K39/245
摘要： We have screened the HCMV-specific T cell clone, 33F4, with a nonamer PS-SCL based on SEQ ID NO: 1, and described a series of analog peptides that are recognized with greater affinity than the native peptide sequence.
摘要翻译：我们已经使用基于SEQ ID NO：1的非对映体PS-SCL筛选了HCMV特异性T细胞克隆33F4，并描述了以比天然肽序列更高的亲和力识别的一系列类似物肽。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式